Skye Bioscience, Inc. (SKYE)

Market Cap	71.24M
Revenue (ttm)	n/a
Net Income (ttm)	-26.57M
Shares Out	30.97M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,281
Open	2.310
Previous Close	2.360
Day's Range	2.180 - 2.380
52-Week Range	1.825 - 17.650
Beta	1.71
Analysts	Buy
Price Target	18.00 (+682.61%)
Earnings Date	Mar 20, 2025

About SKYE

Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: SKYE
• Website: https://skyebioscience.com

Analyst Forecast

According to 7 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price forecast is $18.0, which is an increase of 682.61% from the latest price.

Price Target

$18.0

(682.61% upside)

Analyst Consensus: Buy